Should I buy Boston Scientific (BSX) stock or is it too late?
⭐ The most reliable of them, either direction: Jefferies — 72% of its targets hit on this sector (380 calls tested). It aims for $67 (+44 %), call made on June 25, 2026, maturing on June 25, 2027 (64 d ago).
Firm-by-firm track record on Boston Scientific
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Stifel | 88 % | +36.7 % | 17 | $65 +39% |
| TD Cowen | 100 % | +31.8 % | 5 | $56 +20% |
| Citigroup | 92 % | +30.8 % | 24 | $61 +31% |
| RBC Capital | 88 % | +30.2 % | 17 | $70 +50% |
| Needham | 83 % | +28.2 % | 24 | $57 +22% |
| BTIG | 90 % | +27.3 % | 10 | $60 +29% |
| Canaccord Genuity | 86 % | +23.1 % | 14 | $66 +41% |
| Barclays | 76 % | +22.1 % | 17 | $89 +91% |
✅ Reasons to believe
- 86% of analysts rate it a buy (Buy consensus, 22 ratings) — a sign of market conviction.
- Median price target $67, i.e. +44% from the current price ($47).
- The most reliable firm on BSX, Mizuho (100% hit rate, 4 scored calls), targets $70 (call made on July 15, 2026, maturing on July 15, 2027) (+50%) in its most recent call, and $90 (call made on April 13, 2026, maturing on April 13, 2027) (+93%) in the one coming due soonest.
- 11 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
- Reasonable valuation (P/E ~20) relative to its sector.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 22 ratings, 3 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on BSX
Median target $67 (+44%) · 22 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Boston Scientific now?
We won't decide for you. The facts: 86% of analysts rate it a buy, median target $67 (+44%), and Mizuho (most reliable on BSX, 100%) targets $70. Weigh that against valuation (P/E ~20). This is not personalized advice.
Is it too late to invest in Boston Scientific?
Not according to analysts: the median target ($67) is still +44% above the current price ($47) (most reliable on BSX: Mizuho, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Boston Scientific still worth investing in?
It depends on the gap between the price ($47) and its estimated value: analysts target $67 on median (+44%), with 86% buys (most reliable on BSX: Mizuho, 100%). Cross-check with their real reliability on BSX and the cautions above. Information, not advice.
What's the main risk in buying BSX?
The consensus is not unanimous: of 22 ratings, 3 are neutral.
→ Go deeper: the full Boston Scientific profile (consensus, analyst reliability, price target, performance).